Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 6Recruiting 3Active not recruiting 3Unknown 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 6Carcinoma, Renal Cell 6Squamous Cell Carcinoma of Head and Neck 5Carcinoma, Non-Small-Cell Lung 5Colorectal Neoplasms 3Neoplasms 2Lung Neoplasms 2Hodgkin Disease 2Head and Neck Neoplasms 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Transitional Cell 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Turcot syndrome 1Solid Tumors 1Skin Neoplasms 1Sarcoma, Kaposi 1Sarcoma 1Recurrence 1Rare Tumour 1Prostatic Neoplasms 1Post-Acute COVID-19 Syndrome 1Pancreatic Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Mouth Neoplasms 1Medulloblastoma 1Lung Diseases, Interstitial 1Liver Neoplasms 1Fibrolamellar hepatocellular carcinoma 1

Interventions

Carboplatin 3Radiotherapy, Intensity-Modulated 2Radiotherapy 2selinexor 1ponatinib 1poly ICLC 1pemigatinib 1neratinib 1donafenib 1cobimetinib 1ceritinib 1cemiplimab 1brigatinib 1abemaciclib 1Thymopentin 1Taxes 1Surgical Procedures, Operative 1Standard of Care 1Specimen Handling 1Radiation 1Pluvicto 1Platinum Compounds 1Pemetrexed 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Neck Dissection 1NF protocol 1Magnetic Resonance Spectroscopy 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma × Nivolumab × Clear all
NCT07430202 2026-05-06

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Not yet recruiting
27 enrolled
Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡